Galectin Therapeutics Inc

NASDAQ:GALT  
2.66
+0.05 (+1.92%)
Earnings Announcements

Galectin Therapeutics Inc Says Joel Lewis Assumes CEO Role

Published: 11/09/2020 13:21 GMT
Galectin Therapeutics Inc (GALT) - Galectin Therapeutics Inc - Board Member Joel Lewis Assumes CEO Role.
Galectin Therapeutics Inc - Board Adds Two New Professionals.
Galectin Therapeutics Inc - Innovative Phase 2b/3 Nash-rx Trial in Nash Cirrhosis Initiated.
Galectin Therapeutics Inc - Qtrly Loss per Share $0.10.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.12

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.13

More details on our Analysts Page.